ASCO 2021 | Elevated alpha-fetoprotein in aHCC patients and increased responsiveness to ramucirumab
Augusto Villanueva, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, expresses recent findings from two Phase III clinical trials (NCT01140347, NCT02435433) investigating patients with advanced hepatocellular carcinoma (aHCC) and high alpha-fetoprotein (AFP) treated with ramucirumab (RAM). The study aims to continue to investigate why aHCC patients with elevated AFP may be more responsive to treatment such as RAM and whether this has significant clinical relevance in terms of treatment guidelines for patients with aHCC. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Augusto Villanueva, MD, PhD has received consulting fees from Boehringer Ingelheim, FirstWorld, Cambridge Healthcare Research and Genentech; advisory board fees from BMS, Gilead and NGM Pharmaceuticals; and research support from Eisai.
